|Articles|January 4, 2021
Oracle Health Sciences 2021 Industry Predictions
This industry won't be going back to “the old way.” Oracle GM and SVP, Henry McNamara, makes predictions for sponsors and CROs in 2021.
Advertisement
The shift to decentralized clinical trials and decentralized remote patient monitoring is not going away
The lockdowns of the COVID-19 pandemic had a major impact on clinical trials in 2020, leading to rapid adoption of telemedicine and decentralized trial methods. This will continue in 2021—the industry is not going back to “the old way.” Therefore, sponsors and CROs need to set themselves up to operate successfully in this new model.
The rise in mHealth Data will demand changes to the current eClinical environment
Companies will increasingly turn to mHealth devices to gather data from patients remotely. This increased volume and variety of data coming from these devices will require unified technology platforms capable of collecting, managing, and analyzing it.
Automation will be used to ease the burden on study teams
The pace at which study teams have been working through COVID-19 trials is not sustainable. Despite interest in maintaining this “pandemic speed” of trials, staff simply cannot continue working 20-hour days, seven days a week, technology to streamline repetitive processes, automate trial design, and otherwise reduces the routine workload on professionals.
AI becomes mainstream
Artificial Intelligence (AI) pilot projects among sponsors and CROs in safety case intake and site selection have proven that AI is more effective and accurate than humans in these scenarios. These early successes mean that we’ll soon see AI go mainstream, with great expansion into these applications, as well as many more. As more companies lean into decentralized trials, and as the pace of trials and the amount of data that needs to be analyzed continues to increase, AI will emerge as the only way to process this data efficiently.
Regulators won’t stand in the way of decentralized trials
Regulatory guidance around decentralized clinical trials is widely seen as unclear. Moving forward, as situations require and technology enables a continued shift to decentralized trial methods, regulators will respond and accommodate the adoption of these methods
Henry McNamara is the GM and SVP of Oracle Health Sciences
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Tips to Rescue a Clinical Trial Before It’s Too Late
May 3rd 2024
- Is Trust the Secret Ingredient for Digital Product Success?
December 12th 2023
- FDA Inspections Face Continued Overhaul and Changes
October 13th 2023
- Reaching for the ‘White Spots’ in Rare Disease
September 27th 2023
- The EU Regulations Catching US Pharma Companies Off Guard
September 25th 2023
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5